Clinical Trial Update: Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 trial is evaluating tacrolimus-resistant EBV-specific cytotoxic T lymphocytes for post-transplant lymphoproliferative disorder and related tran…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-transplant Lymphoproliferative Disorder

Drugs mentioned

• Tacrolimus-resistant EBV-specific cytotoxic T lymphocytes (EBV-specific cytotoxic T lymphocytes resistant to tacrolimus)

Snippet

Sponsor: University College, London | Conditions: Post-transplant Lymphoproliferative Disease, Transplant-Related Hematologic Malignancy | EARLY_Phase 1 | Status: ACTIVE_NOT_RECRUITING